Popular Aldi snack recalled due to potential ‘life-threatening' allergen
The U.S. Food and Drug Administration (FDA) issued a notice on Tuesday to announce that Camerican International was recalling 7.05 oz boxes of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream.
The recall was issued because the Aldi brand snack may contain undeclared milk, so consumers with an allergy or 'severe sensitivity to milk run the risk of serious or life-threatening allergic reaction,' per the FDA.
The recalled churro bites were distributed at Aldi stores in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee.
The 7.05 oz cardboard boxes are marked with a 'Best If Used By' date of July 14, 2025, and the Lot Number '01425.'
According to the FDA, the recall was initiated after a 'consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk.' A subsequent investigation revealed the mistake was a result of a 'temporary breakdown in the company's production and packaging processes,' which has since been corrected.
However, there have been no illnesses reported to date due to this product.
Consumers are now urged to return the churro bites to the place of purchase for a full refund.
This isn't the first time Aldi food item to be recalled recently. In May, Santa Monica Seafood of Rancho Dominguez, California, issued a voluntary recall on its Atlantic Salmon Portions with Seafood Stuffing because they may have contained undeclared soy.
The affected salmon portions were sold in three states: California, Nevada, and Arizona. The products were sold in 16-ounce packages and had a use/freeze-by date of June 2, 2025.
The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed.
Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.
Earlier in May, cucumbers sold across the country were recalled after people in 15 states reported getting ill from salmonella. Florida-based Bedner Growers, Inc. recalled the vegetables distributed by Fresh Start Produce Sales, Inc. from April 29 to May 19.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Adorable Cat Helps Scientists Discover New Virus (For Second Time)
A pet cat in Florida may have made scientific history by enabling the discovery of not one but two new strains of viruses. The cat in question, called Pepper, is like many cats, in that he likes to bestow affection on his human companion with thoughtful gifts of dead animals (surprisingly, orcas do this too). So Pepper's owner, University of Florida virologist John Lednicky, decided to take advantage of these usually unwanted and morbid presents. Related: "This was an opportunistic study," says Lednicky. "If you come across a dead animal, why not test it instead of just burying it? There is a lot of information that can be gained." And sampling by cat has so far proven fruitful. When testing an Everglades short-tailed shrew (Blarina peninsulae) procured by Pepper, Lednicky and his colleagues discovered a previously unidentified orthoreovirus. Not much is known about these viruses, but they have, on rare occasions, been linked to stomach flu and meningitis in children. "Mammalian orthoreoviruses were originally considered to be 'orphan' viruses, present in mammals including humans, but not associated with diseases. More recently, they have been implicated in respiratory, central nervous system, and gastrointestinal disease," explains virologist Emily DeRuyter. "There are many different mammalian orthoreoviruses and not enough is known about this recently identified virus to be concerned." So DeRuyter, Lednicky, and colleagues published the sequenced genome of their cat-enabled discovery, to begin the process of better understanding these viruses. It's not the first time Pepper has pawed at science. Last year, the cat gifted Lednicky a mouse containing a jeilongvirus that had never been found in the US before. The strain, Gainesville rodent jeilongvirus 1, is concerningly capable of infecting primate cells, as well as the cells of other mammals. "[This suggests] the virus has a generalist nature with the potential for a spillover event," the researchers wrote in a 2024 paper describing the discovery. "The early detection of endemic viruses circulating within hosts in North-Central Florida can significantly enhance surveillance efforts, thereby bolstering our ability to monitor and respond to potential outbreaks effectively." As well as increasing our ability to detect and monitor a wider range of viruses, these findings also highlight the risks that can come with allowing cats to roam freely outside. A free-ranging cat can kill dozens of animals each year, creating more opportunities for diseases to jump between species. Recently, cats have been flagged as having potential to spread bird flu to their owners as well. Not that Pepper knows anything about any of that. The new virus genome was published in Microbiology Resource Announcements. Emergency Vaccines Reduce Disease Outbreak Deaths by Almost 60% Brain Abnormality in Modern Humans Linked to Ancient Neanderthal DNA One Piece of Advice to Parents Slashed Food Allergies in Children


Business Wire
2 hours ago
- Business Wire
PursueCare to Showcase Digital-First Addiction Treatment and Collaborative Care Models at 2025 Behavioral Health Business Addiction Treatment Forum in Chicago
MIDDLETOWN, Conn.--(BUSINESS WIRE)-- PursueCare, a virtual clinic for substance use disorder (SUD) treatment, will participate in a panel exploring partnerships and strategies for integrated, whole-person care models in behavioral health at the 2025 Behavioral Health Business (BHB) Addiction Treatment Forum in Chicago, Ill., on July 17, 2025, at Convene (311 W Monroe). The forum also spotlights current investment and operational trends shaping the addiction treatment industry. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Share Nicholas Mercadante, Founder and CEO of PursueCare, will join the expert panel titled 'Who's at Quarterback? Ensuring Smooth SUD Handoffs and Building the Partnership Playbook,' slated for 11:30 a.m. CDT. Mercadante will discuss the critical importance of integrated care models and effective handoffs in SUD treatment, drawing on his experience leading a tech-enabled platform designed to meet patients where they are—with convenience, compassion, and clinical excellence. As a former healthcare attorney turned entrepreneur, Mercadante founded PursueCare with a mission to dismantle barriers to addiction treatment by leveraging technology, innovative care delivery, and cross-sector partnerships. Under his leadership, PursueCare has become a leading voice in redefining how providers, payors, and care networks collaborate to treat SUDs holistically. 'Everyone of us at PursueCare is committed to value-based care, our team is dedicated to serving patients in need and shaping industry standards around quality, accessibility, and equity.' Innovation in Action: How PursueCare Is Transforming Addiction Treatment PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, the platform offers: Multidisciplinary care teams include addiction medicine providers, counselors, psychiatrists, and pharmacists. FDA-authorized digital therapeutics — RESET ® and RESET-O ® —that support recovery 24/7 through interactive cognitive behavioral therapy. Integrated pharmacy and lab services through PursueCareRx, enabling seamless medication management and compliance monitoring. Flexible access through a HIPAA-compliant app with support for both scheduled and on-demand visits. Broad insurance acceptance, including Medicare, Medicaid, and most private plans. Mercadante will share the virtual clinic's approach to forging strong partnerships with health systems, employers, and value-based care organizations—offering seamless care coordination, real-time engagement, and outcome-driven models that empower both patients and partners. He'll be joined by fellow industry pioneers Jamie Vinck, President of Meadows Behavioral Health; Beth Keeney, CEO of LifeSpring Health Systems; and Dr. Ayesha Appa, Assistant Professor of Medicine at the University of California, San Francisco. The BHB Forum will offer behavioral health professionals the opportunity to connect, collaborate, and learn from leaders and innovators across the industry. Attendees will include behavioral health professionals, investors, creators, and a range of vendors and service providers. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET ® and RESET-O ®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. For full disclaimers please visit .
Yahoo
2 hours ago
- Yahoo
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA Approval of BLA Would Trigger $40 Million Milestone Payment from Pierre Fabre Laboratories THOUSAND OAKS, Calif., July 14, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. There are no FDA approved therapies in this treatment setting. "The BLA resubmission for tab-cel represents the collaborative efforts with our partner, Pierre Fabre Laboratories, to address the third-party manufacturing facility observations outlined in the January 2025 Complete Response Letter," said Cokey Nguyen, President and Chief Executive Officer of Atara. "We look forward to continued engagement with the FDA throughout its review and with Pierre Fabre Laboratories as they actively prepare for the potential launch of this innovative therapy in the U.S." Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases, including the latest pivotal ALLELE study data that demonstrated a statistically significant 48.8% Objective Response Rate (ORR) (p<0.0001) and favorable safety profile consistent with previous analyses. Tab-cel has been granted Breakthrough Therapy Designation for the treatment of rituximab-refractory EBV-associated lymphoproliferative disease by the U.S. FDA and has orphan drug designation for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders. Corporate Updates Tab-cel Transition Activities: The company is finalizing the transfer of the following clinical studies associated with tab-cel: NCT03394365: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) NCT04554914: A Study to Evaluate Tabelecleucel in Participants with Epstein-Barr Virus-associated Diseases. This study is a multicenter, multicohort, open-label, single-arm, Phase 2 study investigating the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases. Upon completion substantially all operational activities and associated costs related to tab-cel will transfer to Pierre Fabre Laboratories. The sponsorship of the BLA continues to be maintained by Atara. Cash Runway and Future Tabelecleucel (Tab-cel®) Milestone and Royalty Income: Atara projects that its cash, cash equivalents and short-term investments of approximately $22M as of June 30, 2025, combined with the cost reduction initiatives implemented in the first half of 2025, will enable funding of all currently planned operations, including one-time restructuring costs, into the first quarter of 2026, that Atara believes will be sufficient to fund the ongoing activities required to achieve potential BLA approval. Additionally, under its commercialization agreement with Pierre Fabre Laboratories, Atara is eligible to receive a $40 million milestone payment upon FDA approval of the tab-cel BLA, as well as significant double-digit tiered royalties as a percentage of net sales, and milestones related to commercial sales of EBVALLO. The estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary, has not been audited and it is subject to change upon completion of our financial statement closure procedures. Our independent registered public accounting firm has not audited or completed any procedures with respect to this estimate. Such estimates are based on assumptions and plans that are subject to change and such changes could materially impact our expected cash runway. These assumptions include the completion of specific development and regulatory activities by us and actions taken by third parties, and are, therefore, uncertain at this time. Any delay in these activities will create additional expenses and cash needs for us. We have not yet completed our quarter-end financial close process for the quarter ended June 30, 2025. This estimate of our cash, cash equivalents and short-term investments as of June 30, 2025, is preliminary and is subject to change upon completion of our financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of our financial position and results of operations as of and for the quarter ended June 30, 2025. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit and follow @Atarabio on X and LinkedIn. Forward-Looking Statements This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the resubmission of the BLA and potential indications, the timing for FDA review of any resubmission of the BLA, the potential characteristics and benefits of tab-cel, and the results of, and prospects for, the global partnership with Pierre Fabre Laboratories involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Laboratories, including the receipt, timing and amount of any payments to be received by Atara thereunder; (2) Atara's estimate of its cash, cash equivalents, and short-term investments as of June 30, 2025, as well as Atara's cash runway, receipt of potential milestone payments, and operating expenses, including Atara's ability to fund its planned operations into the first quarter of 2026; and (3) Atara's planned transition of substantially all remaining activities relating to tab-cel to Pierre Fabre Laboratories and the timing thereof. Because such statements deal with future events and are based on Atara's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks related with the timing of the transfer of substantially all operational activities related to tab-cel to Pierre Fabre Laboratories, with any potential delay creating additional expenses and cash needs for Atara; risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA feedback and the ability of Atara, Pierre Fabre Laboratories and Pierre Fabre Laboratories third-party manufacturer to address issues identified in the Complete Response Letter (CRL); our ability to access capital, and the sufficiency of Atara's cash resources and access to additional capital on favorable terms or at all; risks and uncertainties related to Atara's financial close and audit procedures; and other risks and uncertainties affecting Atara, including those discussed in Atara's filings with the Securities and Exchange Commission, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. View source version on Contacts Investor and Media Relations Amber DaughertySr. Director, Strategy and Operationsadaugherty@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data